Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
18 déc. 2024 07h00 HE
|
Entrada Therapeutics, Inc.
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
05 nov. 2024 07h00 HE
|
Entrada Therapeutics, Inc.
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
09 oct. 2024 07h00 HE
|
Entrada Therapeutics, Inc.
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
24 sept. 2024 07h00 HE
|
Entrada Therapeutics, Inc.
BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
06 sept. 2024 07h00 HE
|
Entrada Therapeutics, Inc.
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
13 août 2024 07h00 HE
|
Entrada Therapeutics, Inc.
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
Entrada Therapeutics Announces $100 Million Registered Direct Offering
24 juin 2024 07h15 HE
|
Entrada Therapeutics, Inc.
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
24 juin 2024 06h00 HE
|
Entrada Therapeutics, Inc.
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs,...
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
03 juin 2024 07h00 HE
|
Entrada Therapeutics, Inc.
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new...
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
16 mai 2024 07h00 HE
|
Entrada Therapeutics, Inc.
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class...